Concurrent Versus Sequential Radiation Dose Escalation to the Surgical Cavity for Conservative Treatment of High-Risk Early Breast Cancer: NRG/RTOG 1005 Phase III Trial

F Frank A. Vicini (Michigan Healthcare Professionals, Pontiac) K Kathryn Winter (NRG Oncology Statistics and Data Management Center, Philadelphia, PA) G Gary M. Freedman (University of Pennsylvania/Abramson Cancer Center, Philadelphia, PA) D Douglas W. Arthur (Virginia Commonwealth University/Massey Cancer Center, Richmond, VA) B Barry S. Rosenstein S Soren M. Bentzen (University of Maryland/Greenebaum Cancer Center, Baltimore, MD) X X. Allen Li (Medical College of Wisconsin, Milwaukee) M Michele Y. Halyard (Mayo Clinic, Phoenix, AZ) W Wendy A. Woodward R Richard J. Bleicher (Fox Chase Cancer Center, Philadelphia, PA) A Alphonse Taghian (Massachusetts General Hospital Cancer Center, Boston, MA) J Janice Lyons (Case Western Reserve University, Cleveland, OH) J Janice K. Tomberlin (Texas Oncology Bedford, Bedford, TX) S Samantha A. Seaward (Department of Radiation Oncology, Kaiser Permanente Oncology Clinical Trials, Vallejo, CA) S Sally B. Cheston (Central Maryland Radiation Oncology in Howard County, Columbia, MD) A Andrew C. Hoover (University of Kansas Cancer Center, Kansas City, KS) B Bethany M. Anderson F Francisco E. Perera (Verspeeten Family Cancer Centre, London, ON, Canada) M Matthew M. Poppe (Huntsman Cancer Institute, University of Utah, Salt Lake City, UT) I Ivy A. Petersen (Mayo Clinic, Rochester, MN) S Sachin Jhawar (The Ohio State University Comprehensive Cancer Center, Columbus, OH) T Tarek Hijal (McGill University Health Centre, Montreal, QC, Canada) J Jennifer Moughan (Department of Statistics, NRG Oncology Statistics and Data Management Center, Philadelphia, PA) B Benjamin Movsas J Julia R. White (University of Kansas Medical Center Comprehensive Cancer Center, Kansas City)

Abstract

PURPOSE For patients with breast cancer undergoing breast conservation, escalating the dose (boost) of radiation to the lumpectomy cavity after whole-breast irradiation (WBI) reduces ipsilateral breast recurrence (IBR) but extends treatment duration. This phase III trial investigated whether boost delivery during WBI versus after WBI provides noninferior IBR and preserves cosmetic appearance. METHODS NRG/RTOG 1005 randomly assigned patients at higher risk for IBR after lumpectomy and axillary surgery to either a sequential boost of 12 Gy in six fractions(F) or 14 Gy in 7F after WBI of 50 Gy in 25F or 42.7 Gy in 16F (sequential arm) or a concurrent boost of 8 Gy in 15F of 0.53 Gy per day with WBI of 40 Gy in 15F (concurrent arm) using 3-dimensional conformal radiation therapy (RT) or intensity-modulated RT. Based on 1.59% 5-year IBR for the sequential arm, defining the noninferiority margin as a hazard ratio upper limit on the 90% CI of 2.12, 2,312 patients provide 80% power for noninferiority of IBR as first recurrence for the concurrent arm. Secondary end points included disease-free survival and overall survival, adverse events (AEs), and cosmetic outcomes. RESULTS Between May 24, 2011, and June 20, 2014, 2,354 patients were randomly assigned, with 2,255 eligible for analysis (sequential arm, n = 1,118; concurrent arm, n = 1,137). With median follow-up of 7.3 years, there were 56 IBR events; 5- and 7-year IBR were 2.1% and 2.2% on the sequential arm and 1.9% and 2.6% on the concurrent arm, respectively. The noninferiority criterion was met: HR (90% CI): 1.31 (0.84 to 2.04), P = .037. No differences were observed in AEs, cosmetic outcomes, or survival between arms. CONCLUSION Concurrent boost during WBI results in noninferior IBR compared with sequential boost without worsening toxicity or cosmetic outcomes and reduces overall treatment time.

Article Details

Volume / Issue Vol. 44, Issue 19
Published July 01, 2026
Pages 1798-1811
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (25)

F

Frank A. Vicini

Michigan Healthcare Professionals, Pontiac

K

Kathryn Winter

NRG Oncology Statistics and Data Management Center, Philadelphia, PA

G

Gary M. Freedman

University of Pennsylvania/Abramson Cancer Center, Philadelphia, PA

D

Douglas W. Arthur

Virginia Commonwealth University/Massey Cancer Center, Richmond, VA

B

Barry S. Rosenstein

S

Soren M. Bentzen

University of Maryland/Greenebaum Cancer Center, Baltimore, MD

X

X. Allen Li

Medical College of Wisconsin, Milwaukee

M

Michele Y. Halyard

Mayo Clinic, Phoenix, AZ

W

Wendy A. Woodward

R

Richard J. Bleicher

Fox Chase Cancer Center, Philadelphia, PA

A

Alphonse Taghian

Massachusetts General Hospital Cancer Center, Boston, MA

J

Janice Lyons

Case Western Reserve University, Cleveland, OH

J

Janice K. Tomberlin

Texas Oncology Bedford, Bedford, TX

S

Samantha A. Seaward

Department of Radiation Oncology, Kaiser Permanente Oncology Clinical Trials, Vallejo, CA

S

Sally B. Cheston

Central Maryland Radiation Oncology in Howard County, Columbia, MD

A

Andrew C. Hoover

University of Kansas Cancer Center, Kansas City, KS

B

Bethany M. Anderson

F

Francisco E. Perera

Verspeeten Family Cancer Centre, London, ON, Canada

M

Matthew M. Poppe

Huntsman Cancer Institute, University of Utah, Salt Lake City, UT

I

Ivy A. Petersen

Mayo Clinic, Rochester, MN

S

Sachin Jhawar

The Ohio State University Comprehensive Cancer Center, Columbus, OH

T

Tarek Hijal

McGill University Health Centre, Montreal, QC, Canada

J

Jennifer Moughan

Department of Statistics, NRG Oncology Statistics and Data Management Center, Philadelphia, PA

B

Benjamin Movsas

J

Julia R. White

University of Kansas Medical Center Comprehensive Cancer Center, Kansas City